Abstract | OBJECTIVE: Prospective trials specifically designed for elderly patients with advanced non-small-cell lung cancer demonstrating the benefit of platinum-based therapies are still lacking. This trial was designed to clarify whether the addition of cisplatin to monotherapy could improve survival for elderly patients. METHODS: RESULTS: One hundred and twenty-six patients were enrolled. Sixty-three were randomly assigned docetaxel plus cisplatin and 63 docetaxel monotherapy. Median age was 76 years (range 70-88). The second planned interim analysis was performed on 112 assessable patients ( docetaxel/ docetaxel plus cisplatin: 56/56). Although the formal criterion for stopping the trial was not met, the Data and Safety Monitoring Committee recommended study termination on ethical grounds based on the interaction (two-sided P = 0.077, hazard ratios for ≤74/≥75: 0.23/0.72) between age and subgroup and treatment arm, which suggested that docetaxel may not represent an adequate control arm regimen for the age subgroup of 70-74 years. CONCLUSIONS: The interpretation of study results is limited due to early stopping. Further study is needed to confirm survival benefit of platinum-based chemotherapy for elderly non-small-cell lung cancer [UMIN-CTR (www.umin.ac.jp/ctr/) ID: C000000146].
|
Authors | Hiroko Tsukada, Akira Yokoyama, Koichi Goto, Tetsu Shinkai, Masao Harada, Masahiko Ando, Taro Shibata, Yuichiro Ohe, Tomohide Tamura, Nagahiro Saijo, Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG) |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 45
Issue 1
Pg. 88-95
(Jan 2015)
ISSN: 1465-3621 [Electronic] England |
PMID | 25378648
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected]. |
Chemical References |
- Taxoids
- Docetaxel
- Cisplatin
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality, pathology)
- Cisplatin
(administration & dosage)
- Docetaxel
- Drug Administration Schedule
- Female
- Humans
- Japan
- Lung Neoplasms
(drug therapy, mortality, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Prospective Studies
- Quality of Life
- Survival Analysis
- Taxoids
(administration & dosage)
- Treatment Outcome
|